Valuation: MacroGenics, Inc.

Market Cap 306M 268M 247M 231M 434M 28.84B 443M 2.97B 1.15B 14.25B 1.15B 1.12B 49.43B P/E 2026 *
-7.17x
P/E 2027 * -3.15x
Enterprise Value 306M 268M 247M 231M 434M 28.84B 443M 2.97B 1.15B 14.25B 1.15B 1.12B 49.43B EV / Sales 2026 *
1.86x
EV / Sales 2027 * 3.24x
Free-Float
96.57%
Yield 2026 *
-
Yield 2027 * -
1 day+3.22%
1 week+16.46%
Current month+15.62%
1 month+7.61%
3 months+51.26%
6 months+198.76%
Current year+198.76%
1 week 4
Extreme 4
5.08
1 month 3.81
Extreme 3.81
5.08
Current year 1.58
Extreme 1.58
5.08
1 year 1.19
Extreme 1.19
5.08
3 years 0.99
Extreme 0.9897
21.88
5 years 0.99
Extreme 0.9897
29.16
10 years 0.99
Extreme 0.9897
36.48
Manager TitleAgeSince
Chief Executive Officer 53 13/08/2025
Director of Finance/CFO 59 01/05/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 01/09/2001
Director/Board Member 53 13/08/2025
Director/Board Member 62 01/10/2004
Date Insider Type Main position Quantity % Market Cap.
19/05Free

Director

25,750 0.0405%
19/05Free

Director

25,750 0.0405%
19/05Free

Director

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
+3.22%+16.46%+278.74%-11.09% 306M
+0.33%+1.37%+64.03%+119.11% 55.63B
+0.82%+15.05%+79.93%+84.34% 52.25B
+1.36%+0.36%-14.06%-14.69% 23.07B
-1.04%+7.91%+1.61%+419.24% 22.41B
-0.18%+7.20%+32.16%-14.07% 17.32B
-1.10%+4.00%+28.70%-34.51% 15.94B
-3.35%+8.96%+132.20%+290.18% 13.47B
+2.89%+5.51%+27.11%+181.45% 13.77B
+1.31%+0.53%+28.62% - 12.43B
Average +0.43%+5.94%+65.90%+113.33% 22.66B
Weighted average by Cap. +0.27%+5.15%+48.81%+119.98%

Financials

2026 *2027 *
Net sales 164M 144M 133M 124M 233M 15.51B 238M 1.6B 618M 7.66B 617M 604M 26.58B 94.26M 82.65M 76.18M 71.32M 134M 8.89B 137M 916M 354M 4.39B 354M 346M 15.24B
Net income -18.31M -16.05M -14.79M -13.85M -25.97M -1.73B -26.51M -178M -68.81M -853M -68.74M -67.24M -2.96B -127M -111M -103M -96.12M -180M -11.98B -184M -1.23B -478M -5.92B -477M -467M -20.54B
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Employees
293
Date Price Change Volume
26/06/26 USD 4.810 +3.22% 8,516,839
25/06/26 USD 4.660 -2.51% 1,125,686
24/06/26 USD 4.780 +1.92% 1,941,778
23/06/26 USD 4.690 +2.40% 1,491,011
22/06/26 USD 4.580 +10.90% 2,039,946
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.810USD
Average target price
6.750USD
Spread / Average Target
+40.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock